| Patent application number | Description | Published |
|---|
| 20090092544 | Tumor diagnostic agent used in PET comprising anti-ROBO1 antibody - It is an object of the present invention to provide a novel antibody capable of specifically recognizing ROBO1 that is expressed in a cell membrane, a hybridoma that produces the above antibody, a method for producing the above antibody, and a tumor diagnostic agent used in PET comprising the above antibody. The present invention provides a monoclonal antibody capable of specifically recognizing ROBO1 existing on the surface of a cell, which is obtained by immunizing an animal to be immunized with a ROBO1-displaying budded baculovirus recovered from the culture supernatant of host cells infected with a recombinant baculovirus comprising the full-length cDNA of ROBO1 as an antigen. | 04-09-2009 |
| 20100041167 | DRUG FOR DIAGNOSING LARGE INTESTINAL CANCER AND/OR POLYP, OBSERVING POSTOPERATIVE COURSE AND MONITORING RECURRENCE - The present invention is directed to a method for diagnosing large intestinal cancer and/or polyp and a method for observing postoperative course or monitoring recurrence thereof, wherein each method includes detecting cystatin SN protein by use of an anti-cystatin SN antibody. The present invention is able to provide a kit for assaying cystatin SN, which can be used, in a simple manner, in a diagnosis performed prior to conventional barium enema examination and endoscopic examination which impose burdens on patients; as an indicator of metastasis and recurrence; and in the evaluation of therapeutic effects. The present invention provides a method for diagnosing or monitoring large intestinal cancer and/or polyp which can be performed in a simple manner, and thus can allow to design a new regimen rapidly. | 02-18-2010 |
| 20100062449 | Method Of Measuring PTX3 With High Sensitivity - To provide a method of determining vasculopathy, which is a risk factor of myocardial infarction, angiopathic dementia, etc., at an early stage thereof (i.e., mild vasculopathy). The present invention provides a method of determining the severity of mild vasculopathy, including determining PTX3 level in an assay sample by use of an anti-PTX3 monoclonal antibody. | 03-11-2010 |
| 20100093010 | Inhibitor for the Formation of Gamma-Secretase Complex - It is intended to provide an inhibitor for the formation of a γ-secretase complex which comprises a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator as the active ingredient; and use of a cholesterol synthesis inhibitor or a protein geranylgeranylation regulator for producing the same. It is also intended to provide a method of screening a substance having an effect of inhibiting the formation of an active complex of γ-secretase which comprises assaying the activity of inhibiting cholesterol synthesis or quantifying cholesterol accumulated in lipid rafts in cells. It is also intended to provide a method of screening a cholesterol synthesis inhibitor, a protein geranylgeranylation regulator or an HMG-CoA reductase inhibitor which comprises assaying the effect of inhibiting the formation of an active complex of γ-secretase. Moreover, it is intended to provide a method of screening an effect of a test substance on γ-secretase which comprises measuring the distribution of constituents (niscastrin, APH-1, Pen-2 and so on) required by γ-secretase for the formation of its active complex in cells. | 04-15-2010 |
| 20100221766 | NUCLEAR TRANSFER PROMOTER FOR Cdc42 PROTEIN AND METHOD OF SCREENING THE SAME - A nuclear transfer promoter for Cdc42 protein comprising an isoprenoid synthesis inhibitor and/or a geranylgeranyl transferase inhibitor such as an HMG-CoA synthase inhibitor, an HMG-CoA reductase inhibitor, an AMPK activator or a farnesyl pyrophosphoric acid synthase preparation; utilization thereof; a method therefor; a blood vessel remedy comprising the nuclear transfer promoter for Cdc42 protein as the active ingredient; and a method of screening a blood vessel remedy which comprises assaying the ability of Cdc42 protein to transfer into nucleus. | 09-02-2010 |
| 20100247539 | Antibodies that Inhibit Transport Activity of Peptide Transporters - The present inventors discovered that the PepT-binding antibodies have the ability to inhibit the transport activity of peptide transporters, as a result of dedicated research. These antibodies may be utilized as cell growth inhibitors, for example, for treating and preventing cancer. | 09-30-2010 |
